{
    "pmcid": "8221914",
    "qa_pairs": {
        "How does LCB1v1.3 differ from LCB1-Fc in terms of structure and function?": [
            "LCB1v1.3 is a monomeric form optimized for expression yield and solubility, while LCB1-Fc is a bivalent form fused with a human IgG1 Fc domain.",
            "LCB1v1.3 is a bivalent form with an IgG1 Fc domain, while LCB1-Fc is a monomeric form optimized for solubility.",
            "LCB1v1.3 is designed for intranasal delivery, while LCB1-Fc is designed for systemic administration.",
            "LCB1v1.3 targets the spike trimer, while LCB1-Fc targets the nucleocapsid protein."
        ],
        "What are the two miniproteins developed to target the SARS-CoV-2 spike receptor-binding domain?": [
            "LCB1-Fc and LCB1v1.3",
            "LCB1-Fc and LCB2",
            "LCB1v1.3 and LCB2-Fc",
            "LCB1 and LCB1v2.3"
        ],
        "What is the dissociation constant (KD) for LCB1-Fc when binding to the SARS-CoV-2 RBD?": [
            "156 pM",
            "625 pM",
            "14.4 pM",
            "71.8 pM"
        ],
        "What potential advantage does intranasal delivery of LCB1v1.3 offer for COVID-19 treatment?": [
            "Enables self-administration",
            "Increases systemic circulation time",
            "Enhances immune system engagement",
            "Improves binding affinity to the RBD"
        ],
        "Which SARS-CoV-2 variants did LCB1v1.3 show efficacy against?": [
            "B.1.1.7 and strains with E484K and N501Y mutations",
            "B.1.351 and strains with D614G and P681H mutations",
            "P.1 and strains with L452R and T478K mutations",
            "B.1.617.2 and strains with K417N and T20N mutations"
        ]
    }
}